FDAsafety guidance72% confidence
Guidance Documents for Rare Disease Drug Development
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Merck.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Neurology · Alzheimer's Disease
- Sub-indication
- General
Related signal: Merck's MK-2214 Trial Aims to Slow Tau Spread in Early Alzheimer's Disease